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Abstract
Background: The aberrant cell-cycle progression of HIV-1-infected kidney cells plays a major role
in the pathogenesis of HIV-associated nephropathy, however the mechanisms whereby HIV-1
induces infected glomerular podocytes or infected tubular epithelium to exit quiescence are largely
unknown. Here, we ask whether the expression of HIV-1 genes in infected podocytes induces
cyclin D1 and phospho-pRb (Ser780) expression, hallmarks of cyclin D1-mediated G1  S phase
progression.
Results: We assessed cyclin D1 and phospho-pRb (Ser780) expression in two well-characterized
models of HIV-associated nephropathy pathogenesis: HIV-1 infection of cultured podocytes and
HIV-1 transgenic mice (Tg26). Compared to controls, cultured podocytes expressing HIV-1 genes,
and podocytes and tubular epithelium from hyperplastic nephrons in Tg26 kidneys, had increased
levels of phospho-pRb (Ser780), a target of active cyclin D1/cyclin-dependent kinase-4/6 known to
promote G1  S phase progression. HIV-1-infected podocytes showed markedly elevated cyclin
D1 mRNA and cyclin D1 protein, the latter of which did not down-regulate during cell-cell contact
or differentiation, suggesting post-transcriptional stabilization of cyclin D1 protein levels by HIV-1.
The selective suppression of HIV-1 transcription by the cyclin-dependent kinase inhibitor,
flavopiridol, abrogated cyclin D1 expression, underlying the requirement for HIV-1 encoded
products to induce cyclin D1. Indeed, HIV-1 virus deleted of nef failed to induce cyclin D1 mRNA
to the level of other single gene mutant viruses.
Conclusions:  HIV-1 expression induces cyclin D1 and phospho-pRb (Ser780) expression in
infected podocytes, suggesting that HIV-1 activates cyclin D1-dependent cell-cycle mechanisms to
promote proliferation of infected renal epithelium.
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Background
Proliferation and dedifferentiation of HIV-1 infected renal
epithelium is singularly unique compared to the effects of
HIV-1 infection in other non-lymphoid tissues. Indeed,
unlike the atrophy and cell-death of infected central nerv-
ous system [1], cardiac [2], or gastro-intestinal [3] paren-
chyma, aberrant cell-cycle progression of infected renal
epithelium is a defining feature of HIV-associated neph-
ropathy (HIVAN) [4,5]. Yet, the mechanisms are largely
unknown whereby HIV-1 subverts the cell-cycle controls
that normally maintain renal epithelial in G0. Nonethe-
less, several observations from in vitro and in vivo models
of HIVAN pathogenesis suggest that HIV-1 expression it-
self may be a key pathogenic factor. Infection of cultured
podocytes with replication incompetent HIV-1 demon-
strated that HIV-1 gene expression leads to the prolifera-
tion and dedifferentiation of the infected podocytes [6–
8], recapitulating the phenotypes observed in HIVAN
specimens [9,10]. Similarly, renal expression of replica-
tion incompetent HIV-1 proviral transgenes in mice and
rats produces a proliferative renal lesion that is indistigu-
isable both histopathologically and clinically from hu-
man HIVAN [11–14]. These observations raise the
possibility that HIV-1 gene products may interact with mi-
togenic pathways in infected renal epithelium to cause ab-
errant cell-cycle engagement.
In comparison to the two general alternative mechanisms
utilized by known transforming viruses to promote cell-
cycle progression, namely, by activating or bypassing en-
dogenous D-type cyclins (herein, referred to as "cyclin
D"), it has not been established whether HIV-1 gene prod-
ucts trigger either cyclin D-dependent or cyclin D-inde-
pendent proliferation in non-lymphoid tissues [15]. In
infected renal epithelium, HIV-1 could disrupt the inhib-
itory binding of pRb to E2F independent of endogenous
cyclin D, analogous to transforming viral mechanisms
that bypass and down-regulate endogenous cyclin D, such
as SV-40 T antigen binding to pRb [16], HHV-8 v-cyclin
binding to and activating cyclin-dependent kinase-6
(CDK) [17], and activation of cyclin E by EBV-induced c-
myc [18]. Alternatively, HIV-1 could activate cyclin D-de-
pendent proliferation, as exemplified by RSV v-src-medi-
ated signaling [19]. In most tissues, the selective
activation of these cell-cycle pathways is readily discerna-
ble. Indeed, if cells depend on cyclin D-mediated G1  S
transition, passage from G0 through the restriction point
in G1 is dependent on the de novo expression of cyclin D
transcript, accumulation of nuclear cyclin D protein, and
cyclin D/CDK-4/6 phosphorylation of pRb [20]. Then, al-
though nuclear-localized cyclin D decreases in S phase in
individual cells [21], total cyclin D in asynchronously pro-
liferating cell populations remain elevated compared to
quiescent cells [20]. In renal epithelial and mesenchymal
cells, cyclin D1 is the dominant D-type cyclin activated
during cell-cycle progression, both during nephrogenesis
[22] and in non-viral-mediated kidney cell proliferation
[23].
Here, we ask whether infected podocytes expressing HIV-
1 genes show the hallmarks of cyclin D1-dependent pro-
liferation, specifically the up-regulation of cyclin D1 tran-
script and protein expression and the subsequent
phosphorylation of pRb on serine 780, a target site of ac-
tive cyclin D1/CDK-4/6 that is not shared with cyclin E/
CDK-2 complexes [24]. Utilizing two well-characterized
models of HIVAN pathogenesis, HIV-1 transgenic mice
[11–13] and HIV-1 infection of cultured podocytes [6–8]
we find not only these hallmarks of cyclin D1-dependent
proliferation, but also dysregulation of cyclin D1 expres-
sion that normally occurs with cell-cell contact and differ-
entiation [25].
Results
Phospho-pRb (Ser780) expression in vivo
Cyclin D1 is characterized as the major D-type cyclin con-
trolling G1-phase progression in kidney cells, both during
normal and abnormal proliferation [22,23]. To determine
whether cyclin D1 may be active in promoting G1  S
progression in kidneys expressing HIV-1 genes, we uti-
lized a well-characterized HIV-1 transgenic mouse model
(Tg26) of HIVAN [11–13]. Secondary to renal expression
of the HIV-1 NL4-3 gag-pol proviral transgene, adoles-
cent Tg26 transgenics develop a progressive, proliferative
renal disease marked by podocyte and tubular epithelial
hyperplasia that is indistinguishable both clinically and
histopathologically from human HIVAN. In order to de-
termine if cyclin D1 plays a role in this hyperplasia, kid-
neys from three proteinuric 40-day old transgenic siblings
and three non-transgenic littermates were stained by im-
munohistochemistry with antibody to phospho-pRb
(Ser780), a site of cyclin D1/CDK-4/6 phosphorylation
not targeted by cyclin E/CDK-2 complexes that disrupts
pRb/E2F binding for G1  S progression [24]. Figure 1 de-
picts the intense, heterogeneous nuclear staining of
glomerular podocytes and tubular epithelium from hy-
perplastic nephrons in the diseased transgenics versus the
absent staining of nephrons in the non-transgenics con-
sistent with the very low mitotic index in normal kidneys
of adult animals [26]. This suggests that cyclin D1 is pro-
moting cell-cycle progression during the proliferation of
epithelium in diseased kidneys.
Cyclin D1 and phospho-pRb (Ser780) expression in vitro
HIV-1 expression in cultured podocytes recapitulates the
phenotypic abnormalities induced by HIV-1 expression in
infected podocytes in vivo, specifically proliferation, loss
of contact-mediated growth control, and dedifferentiation
[6–8]. To determine if these phenotypes were marked by
enhanced cyclin D1 and phospho-pRb (Ser780) expres-BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/26
Page 3 of 8
(page number not for citation purposes)
sion, we utilized the podocyte cell-culture protocol devel-
oped by Rieser et al. [27,28] to study both sub-confluent
podocyte growth and podocyte growth during the forma-
tion of mature cell-cell contacts at confluence. In this pro-
tocol, normal podocytes are growth-arrested 4–5 days
after initial confluence and are fully differentiated with
mature cell-cell contacts approximately 10 days later. Fig-
ure 2A shows that cyclin D1 message levels are nearly
equivalent between mock ("wild-type")-, control virus-,
and HIV-1-infected subconfluent podocytes, although
only the HIV-1-infected subconfluent podocytes had ele-
vated levels of cyclin D1 protein. In contrast, cell-cell con-
tact in wild-type and control-infected, but not HIV-1-
infected podocytes, caused a severe down-regulation of
cyclin D1 transcript and protein concomitant with the up-
regulation of synaptopodin, a podocyte differentiation
marker [7,28], by the end of the 14-day differentiation pe-
riod. Although HIV-1 infected podocytes showed some
decrease in cyclin D1 message by the end of the differenti-
ation period, cyclin D1 protein levels remained elevated,
suggesting activation by HIV-1 of mechanisms that stabi-
lize cyclin D1 protein levels. Moreover, HIV-1-infected po-
docytes, but not control-infected podocytes, had readily
detectable phospho-pRb (Ser780) at the end of the differ-
entiation period, suggesting that the stably up-regulated
cyclin D1 protein remained active in promoting cell-cycle
progression (Figure 2B). The ongoing proliferation of
HIV-1-infected podocytes following cell-cell contact led to
the formation of multiple foci (Figure 2C) with intense,
heterogenous nuclear cyclin D1 immunofluorescence
consistent with ongoing asynchronous proliferation in
this population of cells (Figure 3). These data indicate that
HIV-1 expression in infected podocytes induces cyclin D1
and phospho-pRb (Ser780) expression, hallmarks of cyc-
lin D1-mediated G1  S progression. The data, however,
do not prove that cyclin D1 expression alone is sufficient
to cause cell-cycle progression.
Requirement of HIV-1 expression for induction of cyclin D1
We sought to further confirm that HIV-1 expression, and
not some idiosyncratic effect of infection, was directly in-
ducing cyclin D1 expression in infected podocytes. First,
Figure 1
In situ immunodetection of phosphorylated serine 780 on pRb in Tg26 kidneys. Phospho-pRb (Ser780) is not
detected in the nuclei of epithelium of normal kidneys (A), but is readily detected in podocytes (short arrows) and tubular epi-
thelial cells (long arrows) in hyperplastic nephrons of diseased transgenic kidneys at cortical (B), juxta-medullary (C), and med-
ullary (D) depths. The prominent staining in many, but not all nuclei, is characteristic of asynchronously proliferating cells.
(magnification = 40)BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/26
Page 4 of 8
(page number not for citation purposes)
Figure 2
Expression of cyclin D1 and phospho-pRb (Ser780) in HIV-1-infected podocytes. (A) Northern and western blot
detection of cyclin D1 expression in wild-type, control-infected, and HIV-1-infected podocytes during subconfluent (SC)
growth at 33C and during 14 days of differentiation of confluent podocytes at 37C shows that neither the cyclin D1 tran-
script nor the elevated cyclin D1 protein in HIV-1-infected podocytes (full-length, singly-spliced, and multiply spliced HIV-1
transcripts) are significantly down-regulated by podocyte cell-cell contact or by podocyte differentiation (synaptopodin tran-
script) when compared to wild-type or control-infected (one transcript from LTR sequences) podocytes. (B) Immunodetec-
tion of phospho-pRb (Ser780) on several phosphorylated forms (arrows) of pRb in the asynchronously proliferating, HIV-1-
infected podocytes that is absent in the quiescent, control-infected podocytes after 14 days of differentiation at 37C. (C)
Abundant foci formation in confluent HIV-1-infected podocytes but not in confluent control-infected podocytes due to the
ongoing proliferation of HIV-1-infected podocytes after cell-cell contact. Blots are representative of two independent experi-
ments.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/26
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we utilized the small molecule cyclin-dependent kinase
inhibitor, flavopiridol, which at low concentrations (e.g.,
less than 100 nM) can selectively suppress HIV-1 tran-
script elongation without altering cellular transcripts in
cell types of various lineages, including podocytes
[7,29,30]. Cyclin D1 transcript levels were followed be-
fore, during, and after treatment of confluent wild-type or
HIV-1 infected podocytes with 50 nM flavopiridol, a dose
that suppresses HIV-1 transcription by 70% [7]. Analysis
of HIV-1, cyclin D1, and glyceraldehyde-3-phosphate de-
hydrogenase (G3PDH) transcript levels in podocytes
treated with flavopiridol for 2 days, followed by drug
washout for 1 day, showed that cyclin D1 expression par-
alleled HIV-1 expression in infected podocytes before,
during and after suppression of HIV-1 genes (Figure 4).
Secondly, we utilized single gene mutants of HIV-1 [8] to
determine which HIV-1 gene(s) may be involved with up-
regulating cyclin D1 expression. Analysis of cyclin D1 tran-
script levels in podocytes infected with HIV-1 singly mu-
tated with premature stop codons in the genes encoding
the various structural and regulatory proteins of HIV-1
(except tat, which is present in every virus) showed that
nef-deficient virus did not significantly up-regulate cyclin
D1 expression when compared to the other mutant viruses
(Figure 5). Taken together, these data indicate that induc-
tion of cyclin D1 expression requires HIV-1 gene expres-
sion and that HIV-1 nef is important for this induction.
Discussion
The mechanisms whereby HIV-1 subverts cell-cycle con-
trols in infected renal epithelium have been unclear. Here,
we demonstrate that podocytes expressing HIV-1 genes
display the hallmarks of cyclin D1-dependent cell-cycle
progression, specifically, that cyclin D1 transcript and pro-
tein expression are markedly up-regulated, and that levels
of phospho-pRb (Ser780), a target of cyclin D1/CDK-4/6
but not cyclin E/CDK-2 complexes [24], are induced in vit-
ro and in vivo. In addition, preliminary micro-array gene
profiling of HIV-1-infected tubular epithelium showed
that cyclin D1 expression is up-regulated several fold
when compared to uninfected tubular epithelium
(Michael Ross, personal communication). This suggests
that the HIV-1-induced proliferation of infected renal ep-
ithelium may be caused by a cyclin D1-dependent mecha-
nism, unlike other viruses that bypass a requirement for
G1-phase cyclins to trigger aberrant cell-cycle progression.
Moreover, normal cellular controls on cell-cycle progres-
sion appears to be dysregulated by HIV-1 expression be-
cause cell-cell contact and differentiation, events that
normally lead to the down-regulation of cyclin D1 expres-
sion [25], did not significantly alter cyclin D1 protein lev-
els in HIV-1 infected podocytes. This suggests a novel
stabilization of cyclin D1 protein in podocytes by HIV-1.
We are exploring whether this occurs from enhanced
translation of cyclin D1 message and/or decreased degra-
dation of cyclin D1 protein and whether other D-type cy-
clins may be involved in phosphorylating pRb in HIVAN.
Prior studies in HIV-1 transgenic animals support the
model that HIV-1 gene products interact with endogenous
mitogenic pathways in infected renal epithelium. [11–
14]. Kidney transplants between normal and transgenic
Tg26 siblings suggested that specific HIV-1 proteins with-
in the kidney, and not circulating factors, transform in-
fected renal epithelium [13]. Indeed, HIV-1 transgenic
mice generated with an HIV-1 proviral construct mutated
in the Nef "PXXP" SH3-binding motif for Src-family ki-
nases failed to develop nephropathy [31], and a recent in
vitro analysis of podocytes infected with single gene mu-
tants of HIV-1 further suggest that Nef plays a central role
in causing the proliferative phenotype in HIVAN [8]. Uti-
lizing these same single gene mutant viruses, we showed
Figure 3
Heterogenous nuclear localization of cyclin D1 in HIV-1-infected podocytes. Immunofluorescent detection of
nuclear cyclin D1 in quiescent, wild-type podocytes after 14 days of differentiation at 37C shows light speckled staining in all
nuclei (A). This differs markedly from the intense nuclear staining of cyclin D1 in some, but not all nuclei, of the asynchronously
proliferating, HIV-1-infected podocytes (GFP positive podocytes) (B and C). (magnification = 100)BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/26
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here that Nef appears to be play a role in the up-regulation
of cyclin D1 by HIV-1 in vitro. Importantly, these single
gene mutants do not exclude the possibility that other
HIV-1 gene(s) may cooperate with nef to induce cyclin D1,
particularly tat, which is present in every virus. Cumula-
tively, however, these observations do suggest a mecha-
nism whereby HIV-1 expression in renal epithelium may
induce cyclin D1: activation of Src-family kinases by Nef
would be expected to up-regulate cyclin D1 gene expres-
sion and promote the synthesis and stabilization of cyclin
D1 protein via Src-Ras-MAPK and Src-PI3K-mTOR signal
transduction pathways, respectively [32–34]. Interesting-
ly, our unpublished in vitro observations and published
data showing marked expression of basic fibroblast
growth factor in the interstitium of HIVAN kidneys [35]
suggest that soluble mitogens may be important cofactors
with HIV-1 expression to induce cyclin D1. Thus, inter-
rupting HIV-1 gene expression should down-regulate cyc-
lin D1 and correct the phenotypic abnormalities in
infected podocytes. In support of this notion, we show
here that cyclin D1 expression parallels HIV-1 expression
before, during, and after suppression of HIV-1 transcrip-
tion with flavopiridol, and recently, we showed that long-
er periods of treatment with flavopiridol ameliorate the
phenotypic abnormalities of infected podocytes [7].
Conclusions
The following results of this study suggest that HIV-1 ex-
pression leads to cyclin D1-mediated G1  S progression
in infected podocytes: cyclin D1 transcript and protein lev-
els are markedly up-regulated, phospho-Rb (Ser780) lev-
els are increased, cyclin D1 protein and phospho-Rb
(Ser780) levels do not decrease with podocyte cell-cell
contact and differentiation, and the up-regulation of cyc-
lin D1 requires the expression of HIV-1 genes, particularly
HIV-1 nef. In sum, these results suggest HIV-induced cell-
cycle mechanisms may contribute to aberrant epithelial
proliferation in HIVAN.
Methods
Podocyte cell culture and infection
Murine podocytes immortalized with interferon-induci-
ble temperature-sensitive SV-40 T antigen (ts-SV-40 T)
were isolated and infected with replication incompetent
GFP-expressing HIV-1 virus, replication incompetent
GFP-expressing single-gene mutants of HIV-1, or replica-
tion incompetent GFP-expressing control lentivirus con-
taining GFP but no HIV-1 genes as previously described
[7,8]. In all cases, 70% to 80% of podocytes showed GFP
expression 4 days post infection (data not shown). Podo-
cytes were used before passage twenty and maintained in
Figure 4
Parallel expression of HIV-1 and cyclin D1. Northern
blot de tection of HIV-1, cyclin D1, and G3PDH transcripts
before (day 14), during (two days with drug, day 16), and
after (one day after drug washout, day 17) treatment of wild-
type and HIV-1-infected podocytes with 50 nM flavopiridol, a
small molecule CDK inhibitor of HIV-1 transcription, show-
ing that cyclin D1 expression parallels HIV-1 expression. Blot
is representative of two independent experiments.
Figure 5
Mapping of HIV-1 genes that induce cyclin D1 expres-
sion. Northern blot detection of cyclin D1 and G3PDH tran-
scripts from wild-type, control-infected, and HIV-1-infected
podocytes infected with single gene mutants of HIV-1 (tat
present in every virus). Similar to wild-type and control-
infected podocytes, podocytes infected with nef-deficient
HIV-1 do not significantly up-regulated cyclin D1 expression
compared to podocytes infected with other single gene
mutant viruses.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/26
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RPMI 1640 (Life Technologies) supplemented with 10%
fetal calf serum, 1  PenStrep (Life Technologies), and 20
U/ml recombinant interferon-gamma (Life Technologies)
at 33C. Unless otherwise indicated, all studies were con-
ducted at cell confluency and 14 days after inactivation of
ts-SV-40 T at the non-permissive temperature (37C)
when wild-type podocytes are fully differentiated [27,28].
Immunohistochemistry
Kidneys from three 40 day-old Tg26 heterozygous trans-
genic siblings demonstrating 2+ proteinuria (Chemstrip
2GP, Roche) and three of their non-transgenics littermates
were collected in accordance with Animal Use and Care
Committee guidelines, fixed (10% buffered formalin),
then paraffin-embedded (Department of Pathology,
Mount Sinai School of Medicine). Four micron full coro-
nal kidney sections from each animal were adhered to
lysine-coated slides and used for immunodetection of
phospho-Rb (Ser780) as follows: sections were deparaffi-
nized and hydrated by placing in xylene for 8 minutes, fol-
lowed by 3 minutes each of 100%, 96%, 80%, 70%, 50%,
30% ethanol, ending with 10 minutes in water; sections
then underwent antigen retrieval (Glyca Reagent, Biogen-
ex) followed by immunodetection (Super Sensitive Detec-
tion Kit, Biogenex) of phospho-Rb (Ser780) after a 12
hour incubation with a 1:1000 dilution of rabbit anti-
phospho-Rb (Ser780) antibody (Cell Signaling) or con-
trol rabbit anti-sera (Biogenex) at 4C.
Immunofluorescence
Following the 14 day podocyte differentiation protocol
on coverslips to establish mature podocytes, wild-type
and HIV-1 infected podocytes underwent immunofluo-
rescent detection of cyclin D1 as follows: coverslips were
washed three times with 1  PBS, fixed in 60% acetone/
3.7% formaldehyde at -20C for 20 minutes, then washed
twice with 1  PBS; the coverslips where then incubated
with a 1:200 dilution of rabbit anti-cyclin D1 antibody
(Santa Cruz Biotechnology) or control rabbit sera (Bio-
genex) for 2 hours at room temperature followed by three
washes with 1  PBS; the coverslips were then incubated
with a 1:250 dilution of rhodamine-labeled donkey-anti-
rabbit anti-sera (Chemicon) for 45 minutes to detect the
primary antibody; following three final washes with 1 
PBS, the coverslips were mounted on glass slides using
ProLong Antifade (Molecular Probes) for fluorescent de-
tection of GFP and cyclin D1 on an Olympus IX70 micro-
scope at 100  magnification.
Podocyte cell-cell contact
Total RNA and protein were extracted from wild-type,
control-infected, and HIV-1 infected podocytes during the
Reiser, et al. protocol to study subconfluent podocyte
growth and podocyte growth during establishment of ma-
ture cell-cell contacts between differentiated podocytes
[27,28]. Briefly, RNA and protein were extracted from par-
allel plates of podocytes using TRIZOL Reagent or RIPA
buffer, respectively, under three conditions: 1) during
sub-confluent growth at 33C; 2) immediately upon
reaching confluency (day zero); and 3) on day 14 after
switching confluent cultures to 37C. At the end of the dif-
ferentiation protocol (day 14), additional plates were
stained to detect foci formation as follows: cells were
washed with 1  PBS, fixed in methanol for 1 minute,
stained with bromophenol blue for 1 minute, then
washed again with 1  PBS. In experiments utilizing the
single gene mutant of HIV-1, total RNA was extract from
infected podocytes 14 days after switching confluent cul-
tures to 37C. All experiments were performed twice.
Flavopiridol treatment
After the 14-day podocyte differentiation protocol de-
scribed above, total RNA was extracted from wild-type
and HIV-1-infected podocytes before treatment with fla-
vopiridol (Developmental Therapeutics Program, Nation-
al Cancer Institute) (day 14), two days after suppression
of HIV-1 transcription with media containing 50 nM fla-
vopiridol (day 16), and one day after drug washout using
media without flavopiridol (day 17). The experiment was
performed twice.
Cyclin D1 transcript and protein
RNA and protein samples were analyzed as follows: Podo-
cyte RNA (10 g) was analyzed by northern blot using
probes for HIV-1 nef-LTR[7], mouse cyclin D1 (cDNA gen-
erated by RT-PCR from mouse podocytes and verified by
sequence analysis), synaptopodin [7], and G3PDH. Fol-
lowing 7.5% SDS/PAGE, podocyte protein (20 g) was
analyzed by western blot for cyclin D1 (ECL detection of a
1:1000 dilution of rabbit anti-cyclin D1 antibody, Santa
Cruz BioTechnology). Protein (250 g) from the control-
infected or HIV-1-infected podocytes on day 14 of the dif-
ferentiation protocol was also analyzed by western blot
for total pRb (ECL detection of a 1:1000 dilution of rabbit
anti-Rb, Santa Cruz Biotechnology) and phospho-Rb
(Ser780) (ECL detection of a 1:500 dilution of rabbit anti-
phospho-Rb (Ser780) antibody binding, Cell Signaling).
Protein concentrations were determined using the Bio-
Rad Protein Assay (Bio-Rad Laboratories), and blotting of
equivalent amounts of protein was confirmed by transient
staining of membranes with Ponceau S solution (0.5%
Ponceau S/1% acetic acid) and by western blot for -actin
(Chemicon). Signal intensity was calculated using the
UN-SCAN-IT gel v4.3 (Silk Scientific).
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